Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Iran Biomed J ; 19(1): 29-34, 2015.
Article in English | MEDLINE | ID: mdl-25605487

ABSTRACT

BACKGROUND: Brain hypoxia-ischemia is a human neonatal injury that is considered a candidate for stem cell therapy. METHODS: The possible therapeutic potential of human umbilical cord blood (HUCB) stem cells was evaluated in 14-day-old rats subjected to the right common carotid occlusion, a model of neonatal brain hypoxia-ischemia. Seven days after hypoxia-ischemia, rats received either saline solution or 4 × 105 HUCB cells i.v. Rats in control group did not receive any injection. After two weeks, rats were assessed using two motor tests. Subsequently, rats were scarified for histological and immunohistochemical analyses. RESULTS: Our immunohistochemical findings demonstrated selective migration of the injected HUCB cells to the ischemic area as well as reduction in infarct volume. Seven days after surgery, we found significant recovery in the behavioral performance in the test group (12.7 +/- 0.3) compared to the sham group (10.0 +/-0.05), a trend which continued to day 14 (15.3 ± 0.3 vs. 11.9 ± 0.5, P<0.05). Postural and motor asymmetries at days 7 and 14 in the test group showed a significant decrease in the percentage of right turns in comparison to the sham group (75% and 59% vs. 97% and 96%, P<0.05). CONCLUSION: The results show the potential of HUCB stem cells in reduction of neurologic deficits associated with neonatal hypoxia-ischemia.


Subject(s)
Brain/cytology , Cord Blood Stem Cell Transplantation , Fetal Stem Cells/transplantation , Hypoxia-Ischemia, Brain/pathology , Hypoxia-Ischemia, Brain/therapy , Adult , Animals , Animals, Newborn , Behavior, Animal/physiology , Brain/pathology , Cell Movement , Disease Models, Animal , Female , Fetal Blood/cytology , Fetal Stem Cells/cytology , Humans , Rats , Rats, Wistar , Young Adult
2.
Postgrad Med J ; 90(1065): 396-401, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24942353

ABSTRACT

Hepatitis B virus (HBV) is the most prevalent infectious agent that can induce severe liver disease. Patients infected with long-term HBV, including chronic, asymptomatic and occult forms, cannot clear HBV from infected hepatocytes completely. It is not clear why some people can clear the infection while others cannot. Furthermore, the main mechanisms responsible for progression of the infections are not fully understood. It has been hypothesised that differences in genetic and immunological parameters between patients and subjects who successfully clear HBV infections are responsible for inducing the long-term forms of the infection. Previous investigations showed that Toll-like receptors (TLRs) play important roles in immune responses, especially innate immunity, against viral infections, including hepatitis B. TLR9 detects intracellular viral dsDNA, which results in the activation of an immune response against HBV. However, defects in this system may result in an attenuated response ultimately leading to long-term HBV infections. Targeting the defects in TLR9 or reactivating the downstream pathways that are normally switched on by TLR9 in response to HBV infection is a new approach to the treatment of long-term HBV infection. However, the pathways and defects seen in patients with long-term HBV need to be thoroughly explored before therapeutics can be applied in the clinical setting. Furthermore, the apparently multigenic nature of long-term HBV infection suggests that treatment of patients may need to be personalised.


Subject(s)
Hepatitis B virus/immunology , Hepatitis B, Chronic/immunology , Immunotherapy/methods , Molecular Targeted Therapy/methods , Toll-Like Receptor 9/immunology , DNA, Viral , Hepatitis B virus/genetics , Hepatitis B, Chronic/genetics , Humans , Immunity, Innate , Ligands , Molecular Targeted Therapy/trends , Signal Transduction
3.
Kaohsiung J Med Sci ; 30(5): 235-42, 2014 May.
Article in English | MEDLINE | ID: mdl-24751386

ABSTRACT

Matrix metalloproteinases (MMPs) play a critical role in the blood-brain barrier permeability and in invasion of the leukocytes into the central nervous system during multiple sclerosis (MS). In this respect, in the present study, we have evaluated the possible role of MMP-9 and MMP-2 on the expression of soluble CD154 (sCD154) and membrane-bound isoform of the CD154 in Iranian MS patients. The expressions of the aforementioned protein-related genes were analyzed at the levels of messenger RNA and proteins by real-time reverse transcription polymerase chain reaction, enzyme-linked immunosorbent assay, and Western blotting. The results showed a high expression of CD154 isoforms, MMP-9 and MMP-2, in MS patients in contrast to controls (p < 0.001). We found an increase in sCD154 concentration (i.e., >3-fold) in patients with a higher MMPs/tissue inhibitor of metalloproteinase 1 (TIMP-1) ratio. Furthermore, secondary-progressive MS patients with exacerbate period showed higher positive correlation between increasing sCD154 concentration and overexpression of MMP-2 (p < 0.001). Our data demonstrate that following the exacerbation period, sCD154 concentration is increased in patients, which is mutually related to the MMPs/TIMP-1 ratio. This relationship may represent a new link between sCD154 concentration and the MMPs/TIMP-1 ratio with prognostic implications.


Subject(s)
CD40 Ligand/blood , Matrix Metalloproteinase 2/blood , Matrix Metalloproteinase 9/blood , Multiple Sclerosis/blood , Multiple Sclerosis/enzymology , Adolescent , Adult , Blotting, Western , CD40 Ligand/genetics , CD40 Ligand/metabolism , Case-Control Studies , Female , Humans , Iran , Male , Middle Aged , Protein Isoforms/blood , RNA, Messenger/genetics , RNA, Messenger/metabolism , Solubility , Tissue Inhibitor of Metalloproteinase-1/metabolism , Young Adult
4.
Viral Immunol ; 27(1): 2-6, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24405101

ABSTRACT

In humans, hepatitis B virus (HBV) is the most prevalent and the main infectious agent that leads to liver disease. Previous investigations identified that long-term HBV-infected patients are unable to eradicate HBV completely from hepatocytes. The main mechanisms responsible for long-term forms of the infections are yet to be clarified. However, researchers believe that the differences in genetic and immunological parameters in the patients in comparison to subjects who successfully clear HBV infections may be the causes for long-term infection. Previous studies demonstrated that chemokines play important roles in the regulation of immune cell migration and activation, which is crucial for a comprehensive immune response against HBV. RANTES, MIP-1α, and MIP-1ß are important CC chemokines which act through CC chemokines receptor 5 (CCR5). This receptor is expressed on several effector immune cells including NK cells, T lymphocytes, and macrophages, and plays a crucial role in the regulation of activation and migration of the immune cells during immune responses against viruses, including HBV. Therefore, alterations in its expression or functions could be associated with attenuated immune responses against HBV. In addition, previous studies identified that a 32 base pair deletion (Δ32) in exon 1, as well as three polymorphisms in the promoter region of the CCR5 gene results in downregulation of the molecule. Previous studies revealed that CCR5 expression was altered in hepatitis B but the role of the CCR5 Δ32 mutation and CCR5 promoter polymorphisms in this disease is controversial. This review addresses the recent information regarding the status of CCR5 expression on immune cells and the association of CCR5 promoter polymorphisms with HBV-infected patients.


Subject(s)
Hepatitis B virus/immunology , Hepatitis B, Chronic/immunology , Receptors, CCR5/genetics , Humans , Killer Cells, Natural/immunology , Macrophages/immunology , Polymorphism, Single Nucleotide , Promoter Regions, Genetic , Receptors, CCR5/biosynthesis , Signal Transduction/immunology , T-Lymphocytes/immunology
5.
J Cardiovasc Thorac Res ; 3(4): 117-22, 2011.
Article in English | MEDLINE | ID: mdl-24250968

ABSTRACT

INTRODUCTION: Human cord blood-derived stem cells are a rich source of stem cells as well as precursors. With regard to the researchers have focused on the therapeutic potential of stem cell in the neurological disease such as stroke, the aim of this study was the investiga-tion of the therapeutic effects of human cord blood-derived stem cells in cerebral ischemia on rat. METHODS: This study was carried out on young rats. Firstly, to create a laboratory model of ischemic stroke, carotid artery of animals was occluded for 30 minutes. Then, umbilical cord blood cells were isolated and labeled using bromodeoxyuridine and 2×10(5) cells were injected into the experimental group via the tail vein. Rats with hypoxic condi-tions were used as a sham group. A group of animals did not receive any injection or sur-geries were used as a control. RESULTS: Obtained results were evaluated based on behavioral responses and immunohistochemistry, with emphasis on areas of putamen and caudate nucleus in the control, sham and experimental groups. Our results indicated that behavioral recovery was observed in the experimental group compared to the either the sham or the control group. However, histological studies demonstrated a low percent of tissue injury in the experimental group in comparison with the sham group. CONCLUSION: Stem cell transplantation is beneficial for the brain tissue reparation after hypoxic ischemic cell death.

SELECTION OF CITATIONS
SEARCH DETAIL
...